Equities research analysts forecast that Genprex Inc (NASDAQ:GNPX) will report ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Genprex’s earnings. Genprex posted earnings per share of ($0.15) during the same quarter last year, which would suggest a negative year-over-year growth rate of 46.7%. The business is expected to announce its next earnings report on Tuesday, November 19th.

According to Zacks, analysts expect that Genprex will report full-year earnings of ($0.87) per share for the current year. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Genprex.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03).

GNPX has been the topic of several research reports. Zacks Investment Research upgraded shares of Genprex from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. ValuEngine upgraded shares of Genprex from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of NASDAQ:GNPX traded down $0.06 on Friday, hitting $0.87. 31,800 shares of the company were exchanged, compared to its average volume of 42,071. The company’s 50 day moving average price is $0.92 and its two-hundred day moving average price is $1.40. Genprex has a one year low of $0.64 and a one year high of $2.56. The firm has a market capitalization of $13.78 million, a price-to-earnings ratio of -0.97 and a beta of 1.44.

An institutional investor recently bought a new position in Genprex stock. Citadel Advisors LLC bought a new stake in Genprex Inc (NASDAQ:GNPX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned 0.20% of Genprex as of its most recent SEC filing. Institutional investors and hedge funds own 5.17% of the company’s stock.

Genprex Company Profile

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Recommended Story: Front-End Load

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.